Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 11, Pages 3467
Publisher
MDPI AG
Online
2020-11-23
DOI
10.3390/cancers12113467
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer
- (2020) Shahrzad Rafiei et al. CANCER RESEARCH
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
- (2020) Johann S. De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells
- (2020) Hongge Wang et al. ONCOGENE
- Overall survival and second primary malignancies in men with metastatic prostate cancer
- (2020) Juha Mehtälä et al. PLoS One
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA Repair and Prostate Cancer: A Field Ripe for Harvest
- (2020) Alan H. Bryce et al. EUROPEAN UROLOGY
- PARP inhibitor resistance: the underlying mechanisms and clinical implications
- (2020) He Li et al. Molecular Cancer
- Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
- (2019) Piper Nicolosi et al. JAMA Oncology
- Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells
- (2019) Nicholas R. Jette et al. BRITISH JOURNAL OF CANCER
- LBA50Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
- (2019) M R Smith et al. ANNALS OF ONCOLOGY
- Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy
- (2019) Nicola J. Curtin et al. Nature Reviews Clinical Oncology
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
- (2019) Lisanne F. van Dessel et al. Nature Communications
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
- (2019) Lauren Montemorano et al. OncoTargets and Therapy
- Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
- (2018) Yi-Mi Wu et al. CELL
- Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012
- (2018) Maha Hussain et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Noel Clarke et al. LANCET ONCOLOGY
- Molecular and cellular mechanisms of castration resistant prostate cancer (Review)
- (2018) Yiqiao Huang et al. Oncology Letters
- PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
- (2018) George E. Ronson et al. Nature Communications
- Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage
- (2018) Catherine Handy Marshall et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
- (2017) Rebecca Gupte et al. GENES & DEVELOPMENT
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
- (2016) Karolina N. Dziadkowiec et al. Przeglad Menopauzalny
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines
- (2014) Eiji Kubota et al. CELL CYCLE
- Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
- (2014) Romana Koppensteiner et al. PLoS One
- Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
- (2013) I. Bajrami et al. CANCER RESEARCH
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Review of Poly (ADP-ribose) Polymerase (PARP) Mechanisms of Action and Rationale for Targeting in Cancer and Other Diseases
- (2013) Julio Morales et al. CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
- (2013) A. Min et al. MOLECULAR CANCER THERAPEUTICS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
- (2013) M. Ihnen et al. MOLECULAR CANCER THERAPEUTICS
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PARP Inhibition Sensitizes to Low Dose-Rate Radiation TMPRSS2-ERG Fusion Gene-Expressing and PTEN-Deficient Prostate Cancer Cells
- (2013) Payel Chatterjee et al. PLoS One
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Guidelines for the management of castrate-resistant prostate cancer
- (2012) Fred Saad et al. CUAJ-Canadian Urological Association Journal
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- Dual Roles of PARP-1 Promote Cancer Growth and Progression
- (2012) M. J. Schiewer et al. Cancer Discovery
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- (2011) J. Chad Brenner et al. CANCER CELL
- The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
- (2010) V. J. Weston et al. BLOOD
- Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2
- (2010) Yvette Drew et al. JNCI-Journal of the National Cancer Institute
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
- (2009) Philip Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started